Lantheus Holdings Inc. (0L8)
Munich
Delayed Data
Oct 13, 2026, 06:00 AM
Day's Range
89.1052 wk Range
43.93Overview - 0L8 - Lantheus Holdings Inc.
Key Statistics
Valuation
Enterprise Value
260.31M
P/E (Trailing)
‪25.20‬
Price / Book
‪4.33‬
EV / EBITDA
‪0.63‬
Profitability
Gross Margin
‪62.30%‬
Profit Margin
‪61.10%‬
Operating Margin
‪21.63%‬
Return on Assets
‪10.48%‬
Return on Equity
‪21.43%‬
Ownership
Shares Outstanding
65.26M
Price stats
50-Day Avg
‪87.69‬
200-Day Avg
‪75.67‬
Peers - 0L8 - Lantheus Holdings Inc.
Peer Comparison
Compared with companies in Drug Manufacturers - Specialty & Generic listed on Munich.
- 0L8MunichLantheus Holdings Inc.+50.44%52-week change25.20P/E (Trailing)‪61.10%‬Profit Margin
- 3KFMunichAuxly Cannabis Group Inc.+95.03%52-week change5.14P/E (Trailing)‪57.26%‬Profit Margin
- HLSMunichAIC Mines Limited+50.81%52-week change—P/E (Trailing)—Profit Margin
- PA8MunichPaion AG+74.44%52-week change-0.83P/E (Trailing)‪94.10%‬Profit Margin
- I76MunichIronwood Pharmaceuticals, Inc. Class A Common Stock+61.59%52-week change21.87P/E (Trailing)—Profit Margin
- NGQ1MunichMedicure Inc.+60.89%52-week change-2.63P/E (Trailing)‪40.71%‬Profit Margin
- 31RMunichRevive Therapeutics Ltd.+48.57%52-week change-0.58P/E (Trailing)—Profit Margin
Profile Summary - 0L8 - Lantheus Holdings Inc.
About
Lantheus Holdings Inc. is a radiopharmaceutical-focused healthcare company that develops, manufactures, and commercializes diagnostic and therapeutic products used to help clinicians detect, localize, and monitor disease. Its portfolio centers on precision diagnostics and nuclear medicine solutions for oncology,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
